Welcome to iSpy-LIFE

Group A Strep (Strep A) infections are a major global health concern. To combat this threat, iSpy-LIFE brings together a diverse team of international researchers. We are working to understand how the immune system responds to Strep A, with the ultimate goal of developing better vaccines and treatments.


Our Mission

Our mission is to advance the understanding of how humans develop immunity to Strep A throughout their lives. By studying natural immunity in children and adults, we aim to identify the mechanisms of protection against Strep A infection.

Our Goal

Our ultimate goal is to use this knowledge to promote the development of effective Strep A vaccines, contributing to the global effort to reduce the burden of Strep A diseases.  

The iSpy-LIFE Network

iSpy-LIFE is a collaborative effort involving nine partner institutions located in the UK, Sweden, Holland, Canada, The Gambia, South Africa, and Australia. Our network is funded by the Leducq Foundation, a philanthropic organisation committed to supporting cardiovascular research.

Our Approach

As highlighted in Imperial College London news article, the iSpy LIFE Network will investigate the body's immune response to Strep A infections to identify the most effective vaccination strategies. This involves studying how the immune system responds to Strep A in diverse populations, including children and adults with varying levels of immunity. The researchers will then use this information to pinpoint the key components of an effective Strep A vaccine.  

  • This multifaceted approach includes:

    • Examining immune responses in diverse populations, including children and adults, as well as individuals with varying levels of immunity and infection history.  

    • Analysing the roles of antibodies, T cells, and other immune system components in protection against Strep A.  

      Our research program aims to:

    • Elucidate the basis of natural acquired immunity to Strep A.  

    • Analyse natural immunity in children and adults through a series of studies in the UK and overseas, including in low and middle-income countries where the burden is greatest.  

    • Facilitate better vaccine development and inform epidemic preparedness.